---
annotation-target: ccr-22-0504.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-30T02:09:13.326Z","text":"肿瘤减积","updated":"2022-08-30T02:09:13.326Z","document":{"title":"ccr-22-0504.pdf","link":[{"href":"urn:x-pdf:57dd9ecd03201af74713997782d8391e"},{"href":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf"}],"documentFingerprint":"57dd9ecd03201af74713997782d8391e"},"uri":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","selector":[{"type":"TextPositionSelector","start":28,"end":37},{"type":"TextQuoteSelector","exact":"Debulking","prefix":"400%  1  Title: Effective Tumor ","suffix":" With Ibrutinib Before Initiatio"}]}]}
>```
>%%
>*%%PREFIX%%400%  1  Title: Effective Tumor%%HIGHLIGHT%% ==Debulking== %%POSTFIX%%With Ibrutinib Before Initiatio*
>%%LINK%%[[#^m7hbth9f809|show annotation]]
>%%COMMENT%%
>肿瘤减积
>%%TAGS%%
>
^m7hbth9f809


>%%
>```annotation-json
>{"created":"2022-08-30T02:10:38.094Z","text":"维奈托克","updated":"2022-08-30T02:10:38.094Z","document":{"title":"ccr-22-0504.pdf","link":[{"href":"urn:x-pdf:57dd9ecd03201af74713997782d8391e"},{"href":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf"}],"documentFingerprint":"57dd9ecd03201af74713997782d8391e"},"uri":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","selector":[{"type":"TextPositionSelector","start":74,"end":84},{"type":"TextQuoteSelector","exact":"Venetoclax","prefix":" Ibrutinib Before Initiation of ","suffix":": Results From the CAPTIVATE Min"}]}]}
>```
>%%
>*%%PREFIX%%Ibrutinib Before Initiation of%%HIGHLIGHT%% ==Venetoclax== %%POSTFIX%%: Results From the CAPTIVATE Min*
>%%LINK%%[[#^ckmvwyjuxf6|show annotation]]
>%%COMMENT%%
>维奈托克
>%%TAGS%%
>
^ckmvwyjuxf6


>%%
>```annotation-json
>{"created":"2022-08-30T02:12:51.297Z","updated":"2022-08-30T02:12:51.297Z","document":{"title":"ccr-22-0504.pdf","link":[{"href":"urn:x-pdf:57dd9ecd03201af74713997782d8391e"},{"href":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf"}],"documentFingerprint":"57dd9ecd03201af74713997782d8391e"},"uri":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","selector":[{"type":"TextPositionSelector","start":7028,"end":7238},{"type":"TextQuoteSelector","exact":" We report tumor debulking and tumor lysis syndrome (TLS) risk category reduction with three cycles of single-agent ibrutinib lead-in before initiation of venetoclax using pooled data from the MRD and FD cohort","prefix":" and Fixed Duration (FD cohort).","suffix":"s. Experimental Design: In both "}]}]}
>```
>%%
>*%%PREFIX%%and Fixed Duration (FD cohort).%%HIGHLIGHT%% ==We report tumor debulking and tumor lysis syndrome (TLS) risk category reduction with three cycles of single-agent ibrutinib lead-in before initiation of venetoclax using pooled data from the MRD and FD cohort== %%POSTFIX%%s. Experimental Design: In both*
>%%LINK%%[[#^yz8a4383xi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^yz8a4383xi


>%%
>```annotation-json
>{"created":"2022-08-30T02:13:45.327Z","updated":"2022-08-30T02:13:45.327Z","document":{"title":"ccr-22-0504.pdf","link":[{"href":"urn:x-pdf:57dd9ecd03201af74713997782d8391e"},{"href":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf"}],"documentFingerprint":"57dd9ecd03201af74713997782d8391e"},"uri":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","selector":[{"type":"TextPositionSelector","start":8358,"end":8780},{"type":"TextQuoteSelector","exact":"Ibrutinib, a once-daily oral Bruton’s tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, are both approved for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (1,2). Together, ibrutinib and venetoclax eliminate both dividing and resting CLL cells through different but complementary modes of action that preferentially affect distinct CLL subpopulations and cell compartment","prefix":"10 August 2022  7  Introduction ","suffix":"s (3-5). In the CAPTIVATE and GL"}]}]}
>```
>%%
>*%%PREFIX%%10 August 2022  7  Introduction%%HIGHLIGHT%% ==Ibrutinib, a once-daily oral Bruton’s tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, are both approved for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (1,2). Together, ibrutinib and venetoclax eliminate both dividing and resting CLL cells through different but complementary modes of action that preferentially affect distinct CLL subpopulations and cell compartment== %%POSTFIX%%s (3-5). In the CAPTIVATE and GL*
>%%LINK%%[[#^4c2r4mj1sbu|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^4c2r4mj1sbu


>%%
>```annotation-json
>{"created":"2022-08-30T02:16:14.062Z","updated":"2022-08-30T02:16:14.062Z","document":{"title":"ccr-22-0504.pdf","link":[{"href":"urn:x-pdf:57dd9ecd03201af74713997782d8391e"},{"href":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf"}],"documentFingerprint":"57dd9ecd03201af74713997782d8391e"},"uri":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","selector":[{"type":"TextPositionSelector","start":9476,"end":10007},{"type":"TextQuoteSelector","exact":"TLS is characterized by electrolyte and metabolic disturbances with laboratory findings of hyperuricemia, hyperkalemia, hyperphosphatemia, and/or hypocalcemia, which can lead to renal insufficiency, cardiac arrhythmias, seizures, and multiorgan failure (9). TLS was identified as an adverse reaction early in the development of venetoclax. Prevention strategies are required to mitigate TLS risk, including standardized dose ramp-up and risk-adapted prophylaxis and monitoring as described in prescribing information for venetoclax","prefix":"nts with high tumor burden (9). ","suffix":" (2). Per venetoclax prescribing"}]}]}
>```
>%%
>*%%PREFIX%%nts with high tumor burden (9).%%HIGHLIGHT%% ==TLS is characterized by electrolyte and metabolic disturbances with laboratory findings of hyperuricemia, hyperkalemia, hyperphosphatemia, and/or hypocalcemia, which can lead to renal insufficiency, cardiac arrhythmias, seizures, and multiorgan failure (9). TLS was identified as an adverse reaction early in the development of venetoclax. Prevention strategies are required to mitigate TLS risk, including standardized dose ramp-up and risk-adapted prophylaxis and monitoring as described in prescribing information for venetoclax== %%POSTFIX%%(2). Per venetoclax prescribing*
>%%LINK%%[[#^38a9d53111k|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^38a9d53111k


>%%
>```annotation-json
>{"created":"2022-08-30T02:17:27.426Z","updated":"2022-08-30T02:17:27.426Z","document":{"title":"ccr-22-0504.pdf","link":[{"href":"urn:x-pdf:57dd9ecd03201af74713997782d8391e"},{"href":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf"}],"documentFingerprint":"57dd9ecd03201af74713997782d8391e"},"uri":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","selector":[{"type":"TextPositionSelector","start":13875,"end":15015},{"type":"TextQuoteSelector","exact":"Tumor burden was assessed by radiographic evaluation of the sum of the products of perpendicular diameters (SPD) of target lymph nodes and craniocaudal spleen length using computed tomography or magnetic resonance imaging, and by absolute lymphocyte count (ALC). Radiographic evaluation was performed at baseline and at the end of cycle 3 (before venetoclax initiation in cycle 4). ALC and serum creatinine were assessed at baseline, on day 1 of cycles 2 and 3, at the end of cycle 3 (before venetoclax initiation in cycle 4), and at 24 hours prior to each venetoclax ramp-up (weeks 2–4 of cycle 4 and week 1 of cycle 5). Additional hematology and serum chemistry samples were collected at 6–8 hours and at 24 hours after the first dose of each venetoclax ramp-up for patients in the high-risk category for TLS, as recommended per venetoclax prescribing information (2). Creatinine clearance was calculated using the Cockcroft-Gault formula. Tumor burden categories for TLS risk (Supplementary Table S1) were assessed at baseline and before venetoclax initiation in cycle 4 using criteria described in venetoclax prescribing information (2)","prefix":"d TLS risk category assessments ","suffix":".   TLS monitoring assessments T"}]}]}
>```
>%%
>*%%PREFIX%%d TLS risk category assessments%%HIGHLIGHT%% ==Tumor burden was assessed by radiographic evaluation of the sum of the products of perpendicular diameters (SPD) of target lymph nodes and craniocaudal spleen length using computed tomography or magnetic resonance imaging, and by absolute lymphocyte count (ALC). Radiographic evaluation was performed at baseline and at the end of cycle 3 (before venetoclax initiation in cycle 4). ALC and serum creatinine were assessed at baseline, on day 1 of cycles 2 and 3, at the end of cycle 3 (before venetoclax initiation in cycle 4), and at 24 hours prior to each venetoclax ramp-up (weeks 2–4 of cycle 4 and week 1 of cycle 5). Additional hematology and serum chemistry samples were collected at 6–8 hours and at 24 hours after the first dose of each venetoclax ramp-up for patients in the high-risk category for TLS, as recommended per venetoclax prescribing information (2). Creatinine clearance was calculated using the Cockcroft-Gault formula. Tumor burden categories for TLS risk (Supplementary Table S1) were assessed at baseline and before venetoclax initiation in cycle 4 using criteria described in venetoclax prescribing information (2)== %%POSTFIX%%.   TLS monitoring assessments T*
>%%LINK%%[[#^8heggdx3g14|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8heggdx3g14


>%%
>```annotation-json
>{"created":"2022-08-30T02:19:25.334Z","updated":"2022-08-30T02:19:25.334Z","document":{"title":"ccr-22-0504.pdf","link":[{"href":"urn:x-pdf:57dd9ecd03201af74713997782d8391e"},{"href":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf"}],"documentFingerprint":"57dd9ecd03201af74713997782d8391e"},"uri":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/ccr-22-0504.pdf","selector":[{"type":"TextPositionSelector","start":26584,"end":27109},{"type":"TextQuoteSelector","exact":"In conclusion, tumor debulking with three cycles of single-agent ibrutinib reduces tumor burden category for TLS risk prior to venetoclax initiation, resulting in avoidance of hospitalization during venetoclax initiation in a large proportion of patients with high baseline risk of TLS. Ibrutinib plus venetoclax represents an all-oral, once-daily, chemotherapy-free, time-limited regimen that offers patient convenience and ease of administration and can be delivered in the outpatient setting for most patients with CLL/SLL","prefix":"nse to COVID vaccination (20).  ","suffix":".  Acknowledgments We thank the "}]}]}
>```
>%%
>*%%PREFIX%%nse to COVID vaccination (20).%%HIGHLIGHT%% ==In conclusion, tumor debulking with three cycles of single-agent ibrutinib reduces tumor burden category for TLS risk prior to venetoclax initiation, resulting in avoidance of hospitalization during venetoclax initiation in a large proportion of patients with high baseline risk of TLS. Ibrutinib plus venetoclax represents an all-oral, once-daily, chemotherapy-free, time-limited regimen that offers patient convenience and ease of administration and can be delivered in the outpatient setting for most patients with CLL/SLL== %%POSTFIX%%.  Acknowledgments We thank the*
>%%LINK%%[[#^jld7zckt2i9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jld7zckt2i9
